The engineered minimal TIMP variants, particularly mTC1 and mTC3, exhibit a strong potential for inhibiting GBM cell migration similar to wild-type TIMPs, and this substantial reduction in the migration of T98G and A172 cells highlights their efficacy as potential therapeutic agents for GBM. This evidence concerns the gene RET and glioblastoma.